Clinical trials: Hepatitis B, completed
Liver Dysfunction, Immune Suppression
Optimizing HBV Management During Anti-CD20 Antibodies
Hepatitis B virus (HBV) reactivation is common during anti-CD20 containing chemotherapy, even in HBsAg-negative patients with only prior HBV exposure.
- Conditions
- Liver Dysfunction, Immune Suppression, Hepatitis B
- Trial name
- NCT03155984
- Testing
- Anti-CD20 antibody
- Where
- Hong Kong
- Volunteers
- 83 people
- Sponsor
- The University of Hong Kong
Hepatitis B, Hepatitis C
Observational Study on Prevalence of Host and Viral Genotypes in Chronic Hepatitis B and Hepatitis C Patients in India
This study will define the substantial disease burden associated with viral hepatitis in India, and provide a foundation to understand the host and viral determinants of disease pathogenesis that may ultimately impact treatment…
- Trial name
- NCT01772121
- Where
- 19 sites in India
- Volunteers
- 1,000 people
- Sponsor
- Gilead Sciences
Hepatitis c
Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Tablet Plus Ribavirin Tablet (Part A) Versus Single Dose (2 Tablets) of EHCV Containing Sofosbuvir, Ribavirin, and Natural Anti-hemolytic (B) in Egyptian Adults With Chronic Genotype 4 HCV Infection
Two Groups of Genotype 4 HCV Patients will participate through open-label randomized Study comparing Sofosbuvir tablet Plus Ribavirin tablet (Part A) versus single Dose (2 tablets) of EHCV containing Sofosbuvir, Ribavirin, and…
- Trial name
- NCT02483156
- Testing
- Two tablets of EHCV in Single Dose each tablet containing SOF 200 mg, RBV 500 mg and Natural anti-hemolytic (AH) at 200 mg, Sofosbuvir tablet (SOF) 400 mg - once daily, Ribavirin (RBV) 1000 mg - splitted on 2 doses daily - 600 mg on morning and 400 mg on evening
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Egyptian Liver Hospital
Inflammatory Bowel Disease
Hepatitis B Vaccine in Patients With Inflammatory Bowel Disease
The objective is to assess the efficacy of Hepatitis B Virus vaccination in a population of IBD patients treated with immunosuppressive medications.
- Trial name
- HBV VIP (NCT01531075)
- Testing
- ENGERIX-B (HBV Vaccine), Sci-B-Vac
- Where
- Israel
- Volunteers
- 91 people
- Sponsor
- Soroka University Medical Center
Chronic Hepatitis B
A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-H3733 in Subjects With Chronic Hepatitis B Virus Infection
This is a randomized, blinded, placebo-controlled, dose-ranging Phase 1b study of the safety, PK, and antiviral activity of ABI-H3733 in treatment-naïve or off-treatment chronic Hepatitis B virus (cHBV) subjects that are…
- Trial name
- NCT05414981
- Testing
- ABI-H3733
- Where
- 9 sites in Bulgaria, Hong Kong and 4 more
- Volunteers
- 31 people
- Sponsor
- Assembly Biosciences
Hepatitis B, Chronic
Drug Drug Interaction Study for EYP001 With Entecavir
This is a Phase 1, single-center, open-label, three subsequent dosing periods study to evaluate the drug-drug-interaction (DDI), pharmaco-kinetics (PK) and pharmacodynamics (PD), safety, and tolerability of a single dose of…
- Trial name
- NCT03469583
- Testing
- EYP001, Entecavir 1 MG
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Enyo Pharma
Hepatocellular Carcinoma
A Study of TCR-Redirected T Cell Infusion to Prevent Hepatocellular Carcinoma Recurrence Post Liver Transplantation
Hepatocellular Carcinoma (HCC) recurrence rate is high among liver transplant patients, while treatment measures are limited. This study plans to recruit 39 subjects with Hepatitis B virus (HBV) related HCC after liver…
- Trial name
- NCT02686372
- Testing
- TCR-T, No intervention and TCR-T (at crossover)
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Lion TCR Pte. Ltd.
Chronic Hepatitis B
Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B
This study is aimed to assess the efficacy and safety of Peginterferon alfa-2b (40kD, Y-shape), in a dose of 180μg/week, in chronic hepatitis B patients, and collects sufficient evidences for the listed of the studied drug.
- Trial name
- NCT01760122
- Testing
- Ypeginterferon alfa-2b, Pegasys
- Where
- 43 sites in China
- Volunteers
- 820 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Chronic Hepatitis b
Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir.
Treatment of CHB patients with genotypic resistance to NUCs has been problematic due to the lack of data from randomized trials.
- Trial name
- NCT03241641
- Testing
- Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate
- Where
- South Korea
- Volunteers
- 174 people
- Sponsor
- Young-Suk Lim
Hepatitis B
Persistence of the Immune Response to Hepatitis B in 4-6 Years Old Children Previously Vaccinated With DTPa-HBV-IPV/Hib
Persistence of seroprotective antibody concentrations \& immunological memory shown by the ability to mount a response to a challenge dose of HBV vaccine
- Trial name
- NCT00335881
- Testing
- hepatitis B vaccine
- Where
- 38 sites in Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B, Chronic, Chronic Kidney Diseases
Renoprotective Effects of Telbivudine in Chronic Hepatitis B
Renal impairment is common in patients with chronic hepatitis B infection. For those taking nucleotide analogues, renal toxicity of adefovir disoproxil (ADV) and tenofovir disoproxil fumarate (TDF) is a significant concern in…
- Trial name
- NCT03778567
- Testing
- Telbivudine
- Where
- Hong Kong
- Volunteers
- 31 people
- Sponsor
- The University of Hong Kong
HIV Infections
Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients
In HIV infected patients, individuals exposed to the virus of Hepatitis B are more susceptible to develop a chronic and severe liver disease with a major risk of cirrhosis and liver cancer.
- Trial name
- VIHVAC-B (NCT00480792)
- Testing
- GenHevac B Pasteur
- Where
- France
- Volunteers
- 437 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Chronic Hepatitis B
GLS4/RTV and TAF Drug-drug Interaction
The purpose of this study is to evaluate the drug-drug-interaction (DDI), pharmacokinetics (PK) and tolerability of GLS4/RTV combined with TAF in healthy subjects.
- Trial name
- NCT04551261
- Testing
- GLS4, RTV, TAF
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Hepatitis B
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH-006 in Healthy Volunteers
Huahui Health is developing a treatment for Hepatitis B virus. This study is designed to evaluate the safety and tolerability of HH-006, a hepatitis virus neutralizing monoclonal antibody in healthy volunteers, and to determine…
- Trial name
- NCT05275465
- Testing
- HH-006
- Where
- Australia
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Huahui Health
Hepatitis B, Chronic
Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection
The purpose of this study was to determine the safety and anti-hepatitis B virus (-HBV) activity of ACH-126,443 in comparison to lamivudine or placebo in treatment-naive adults with chronic hepatitis B infection.
- Trial name
- NCT00034359
- Testing
- ACH-126,443, Lamivudine
- Where
- 3 sites in Bulgaria, Federal Republic of Yugoslavia
- Volunteers
- 79 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Chronic Hepatitis B
An Study of Efficacy and Safety of Clevudine
Randomized, double blind parallel group, positive control, multi-center trial. Patients will be randomized at 1:1 ratio in group A or group B
- Trial name
- NCT01192854
- Testing
- Clevudine, Adefovir
- Where
- China
- Volunteers
- 288 people
- Sponsor
- Eisai Co., Ltd.
Compensated Chronic Hepatitis B
Efficacy Optimizing Research of Lamivudine Therapy
The purpose of this study is to compare the adefovir early add-on to rescue therapy strategy, and also explore the efficacy of Lamivudine and adefovir de-novo combination therapy.
- Trial name
- EXPLORE (NCT01088009)
- Testing
- lamivudine, lamivudine, adefovir
- Where
- 24 sites in China
- Volunteers
- 366 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatitis B, Chronic
Suboptimal Responders to Adefovir Switching to Entecavir
Switching to Entecavir will result in superior antiviral efficacy as compared to continuing with Adefovir in patients with a suboptimal response to Adefovir
- Trial name
- NCT00718887
- Testing
- Entecavir, Adefovir/Entecavir
- Where
- 8 sites in China
- Volunteers
- 228 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis B With Hepatic Fibrosis
A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver Fibrosis
This is an open-label, single-arm study designed to collect safety data on hydronidone capsules in patients with chronic hepatitis B virus infection accompanied by liver fibrosis or fatty liver disease accompanied by liver…
- Trial name
- NCT07364448
- Testing
- Hydronidone capsules
- Where
- China
- Volunteers
- 411 people
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Hepatitis B
Immune Response to Hepatitis B Vaccine Challenge Dose in Subjects Who Received a Primary Neonatal Hepatitis B Vaccine.
The current study will evaluate immunological memory to hepatitis B antigen in subjects who received primary neonatal vaccination of hepatitis B vaccine (Engerix™-B ), 20 years ago in the primary study and who have anti-HBs…
- Trial name
- NCT00456625
- Testing
- Engerix™-B
- Where
- Thailand
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.